Abstract
Dear Editor, We read the recent report by Narvaez et al. [1] in Osteoporosis International regarding the ineffectiveness of 8 months of treatment with teriparatide in the management of osteonecrosis of the jaw (ONJ) with interest. The authors mention that impaired immune function secondary to treatment with rituximab and methotrexate might have confounded the results of the teriparatide treatment and hence correctly conclude that further studies are warranted to test the therapeutic effectiveness of teriparatide in ONJ. In addition, we would like to make the following comments:
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
